Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 1568-1574, 2006. First published June 8, 2006; 10.1373/clinchem.2006.069039
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 069039.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2006.069039v1
52/8/1568    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kort, S. A.R.
Right arrow Articles by Blankenstein, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kort, S. A.R.
Right arrow Articles by Blankenstein, M. A.
Related Collections
Right arrow Cancer Diagnostics (since 2002)
Right arrow Proteomics and Protein Markers
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2006;52:1568-1574.)
© 2006 American Association for Clinical Chemistry, Inc.

Automation and Analytical Techniques

Comparison of 6 Automated Assays for Total and Free Prostate-Specific Antigen with Special Reference to Their Reactivity toward the WHO 96/670 Reference Preparation

Sheila A.R. Kort1, Frans Martens1, Hilde Vanpoucke2, Hans L. van Duijnhoven3 and Marinus A. Blankenstein1,a

1 Endocrine Laboratory, Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands.
2 Laboratory of Clinical Chemistry, H. Hartziekenhuis, Roeselare-Menen vzw, Belgium.
3 Algemeen Klinisch Laboratorium, Elkerliek Ziekenhuis, Helmond, The Netherlands.

aAddress correspondence to this author at: Department of Clinical Chemistry, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Fax 31-20-4443895; e-mail MA.Blankenstein{at}vumc.nl.

Background: Prostate-specific antigen (PSA) assays have historically produced different results. Our aim was to investigate the comparability of assay results of selected commercially available assay methods designed to measure total, free, or complexed PSA (tPSA, fPSA, and cPSA).

Methods: We measured tPSA, fPSA, and cPSA in 70 samples and in the WHO PSA 96/670 reference preparation with 6 assays (Beckman-Coulter Access, Abbott ARCHITECT and AxSYM, Bayer Advia Centaur, DPC IMMULITE 2000, and Roche Modular Analytics E170). We also calculated the fPSA/tPSA ratio.

Results: The mean deviations from the expected tPSA and fPSA values for the WHO 96/670 reference preparation were 0.37 (range, 0.01–1.32) and 0.19 (range, 0.05–0.49) µg/L, respectively. When plotted against the expected WHO 96/670 reference preparation value, regression slopes varied from 0.99 to 1.22 and r2 from 0.9996 to 1.000. When total PSA was measured in mixtures of sera with high and low tPSA concentrations, the mean (SD) slope of regression of different assays against an in-house method was 1.04 (0.09). In these specimens, the fPSA/tPSA ratio was 0.11–0.14 with different methods. The tPSA and fPSA values in patient samples measured in different assays and plotted against ARCHITECT gave regression slopes from 0.88 to 0.97. The results of the studied assays for tPSA in serum samples agreed within 15%, from each other, and all results for the WHO 96/670 reference preparation were within 6.8% (confidence interval, 1.7%–15.2%) of the expected value. The results for fPSA were more diverse.

Conclusions: Differences among PSA assays appear to have decreased since introduction of the WHO 96/670 reference preparation, but further efforts are needed to harmonize fPSA assays.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem., December 1, 2008; 54(12): e11 - e79.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
F. H. Jansen, M. Roobol, C. H. Bangma, and R. H. N. van Schaik
Clinical Impact of New Prostate-Specific Antigen WHO Standardization on Biopsy Rates and Cancer Detection
Clin. Chem., December 1, 2008; 54(12): 1999 - 2006.
[Abstract] [Full Text] [PDF]

Home page
 Ann Clin BiochemHome page
D. B. P. Eekers, A. Laschet, M. de Groot, E. Roelofs, A. Kester, K. Delaere, P. Lambin, F. van Gils, M. Nap, and J. ten Kate
Why determine only the total prostate-specific antigen, if the free-to-total ratio contains the information?
Ann Clin Biochem, May 1, 2008; 45(3): 270 - 274.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.